Myc 生物学的兴衰。
The ups and downs of Myc biology.
机构信息
Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143-0502, USA.
出版信息
Curr Opin Genet Dev. 2010 Feb;20(1):91-5. doi: 10.1016/j.gde.2009.11.001. Epub 2009 Dec 3.
Abstract
The basic helix-loop-helix protein Myc is a renowned transcription factor controlling disparate aspects of cell physiology that, together, allow efficient proliferation of somatic cells. This ability, together with the observation that its deregulated expression occurs in the majority of human cancers, suggests that Myc could be a good therapeutic target. However, several aspects of Myc biology remain elusive: what is the major difference between oncogenic and physiological Myc? How does oncogenic Myc evade the intrinsic tumor surveillance pathways provided by evolution? If Myc inhibition were even possible, what would be the consequences for the homeostasis of normal proliferating tissues versus the fate of cancer cells? Here we summarize the latest works addressing these issues.
摘要
碱性螺旋-环-螺旋蛋白 Myc 是一种众所周知的转录因子，可控制细胞生理学的不同方面，这些方面共同使体细胞的有效增殖成为可能。这种能力，以及观察到其失调表达发生在大多数人类癌症中的事实，表明 Myc 可能是一个很好的治疗靶点。然而，Myc 生物学的几个方面仍然难以捉摸：致癌和生理 Myc 之间的主要区别是什么？致癌 Myc 如何逃避进化提供的内在肿瘤监测途径？如果 Myc 抑制甚至成为可能，对正常增殖组织的动态平衡和癌细胞的命运会有什么影响？在这里，我们总结了最新的研究成果，以解决这些问题。
相似文献
1
The ups and downs of Myc biology.Myc 生物学的兴衰。
Curr Opin Genet Dev. 2010 Feb;20(1):91-5. doi: 10.1016/j.gde.2009.11.001. Epub 2009 Dec 3.
2
Energy regulation: HIF MXIes it up with the C-MYC powerhouse.能量调节：缺氧诱导因子（HIF）与C-MYC这一强大动力因素相互作用。
Dev Cell. 2007 Jun;12(6):845-6. doi: 10.1016/j.devcel.2007.05.006.
3
In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.Myc-Max相互作用的体内定量与扰动及其对致癌潜力的影响。
Oncotarget. 2014 Oct 15;5(19):8869-78. doi: 10.18632/oncotarget.2588.
4
The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.c-MYC癌蛋白作为癌症及其他细胞生长紊乱疾病的治疗靶点。
Expert Opin Ther Targets. 2003 Oct;7(5):623-42. doi: 10.1517/14728222.7.5.623.
5
Low molecular weight inhibitors of Myc-Max interaction and function.Myc-Max相互作用及功能的低分子量抑制剂
Oncogene. 2003 Sep 18;22(40):6151-9. doi: 10.1038/sj.onc.1206641.
6
An "-omycs" Toolbox to Work with MYC.用于 MYC 的 "-omycs" 工具箱。
Methods Mol Biol. 2021;2318:1-11. doi: 10.1007/978-1-0716-1476-1_1.
7
The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.Myc原癌蛋白的碱性区域/螺旋-环-螺旋/亮氨酸拉链结构域：功能与调控
Oncogene. 1999 May 13;18(19):2955-66. doi: 10.1038/sj.onc.1202750.
8
Translocations involving c-myc and c-myc function.涉及c-myc的易位及c-myc功能
Oncogene. 2001 Sep 10;20(40):5595-610. doi: 10.1038/sj.onc.1204595.
9
Mnt takes control as key regulator of the myc/max/mxd network.Mnt作为myc/max/mxd网络的关键调节因子发挥控制作用。
Adv Cancer Res. 2007;97:61-80. doi: 10.1016/S0065-230X(06)97003-1.
10
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.雷公藤红素及雷公藤红素类三萜对c-Myc-Max异二聚体的直接抑制作用。
Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116.
引用本文的文献
1
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways.表皮生长因子受体（EGFR）、KRAS和MYC癌基因的动态多级调控：通过（表观）遗传及转录后/翻译途径驱动癌细胞增殖
Cancers (Basel). 2025 Jan 14;17(2):248. doi: 10.3390/cancers17020248.
2
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.药物发现与治疗进展中蛋白质-蛋白质相互作用调节剂的新见解。
Signal Transduct Target Ther. 2024 Dec 6;9(1):341. doi: 10.1038/s41392-024-02036-3.
3
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.FGF/FGFR/c-Myc 轴作为多发性骨髓瘤有前景的治疗靶点。
J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2.
4
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.外泌体介导的siRNA分子在癌症治疗中的应用：成就与挑战
Front Mol Biosci. 2024 Sep 17;11:1447953. doi: 10.3389/fmolb.2024.1447953. eCollection 2024.
5
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.MYC 和 KRAS 合作：癌症治疗机遇中的历史挑战。
Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z.
6
Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk.负载二氧化钛纳米结构的阿霉素克服乳腺癌治疗中的耐药性：ABCA/P53/C- myc相互作用
Future Sci OA. 2024 May 15;10(1):FSO979. doi: 10.2144/fsoa-2023-0107. eCollection 2024.
7
Changes in spindle morphology driven by TPX2 overexpression in MYC-driven breast cancer cells.MYC驱动的乳腺癌细胞中TPX2过表达所驱动的纺锤体形态变化。
MicroPubl Biol. 2024 Apr 10;2024. doi: 10.17912/micropub.biology.001182. eCollection 2024.
8
Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative Breast Cancer.揭示柴芍疏肝方抗三阴性乳腺癌的机制
Drug Des Devel Ther. 2024 Apr 10;18:1115-1131. doi: 10.2147/DDDT.S394287. eCollection 2024.
9
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.核质转运是 MYC 驱动的肝细胞癌的可靶向依赖性。
Nat Commun. 2024 Feb 1;15(1):963. doi: 10.1038/s41467-024-45128-y.
10
Lessons in aging from Myc knockout mouse models.来自Myc基因敲除小鼠模型的衰老研究经验。
Front Cell Dev Biol. 2023 Aug 9;11:1244321. doi: 10.3389/fcell.2023.1244321. eCollection 2023.
本文引用的文献
1
Myc-regulated microRNAs attenuate embryonic stem cell differentiation.Myc调控的微小RNA减弱胚胎干细胞分化。
EMBO J. 2009 Oct 21;28(20):3157-70. doi: 10.1038/emboj.2009.254. Epub 2009 Sep 10.
2
Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation.肠道上皮中Myc的急性过表达重现了Wnt/β-连环蛋白信号通路激活所引发的部分而非全部变化。
Mol Cell Biol. 2009 Oct;29(19):5306-15. doi: 10.1128/MCB.01745-08. Epub 2009 Jul 27.
3
Distinct thresholds govern Myc's biological output in vivo.不同的阈值在体内调控Myc的生物学效应。
Cancer Cell. 2008 Dec 9;14(6):447-57. doi: 10.1016/j.ccr.2008.10.018.
4
Functional integration of microRNAs into oncogenic and tumor suppressor pathways.微小RNA在致癌和抑癌通路中的功能整合。
Cell Cycle. 2008 Aug 15;7(16):2493-9. doi: 10.4161/cc.7.16.6452. Epub 2008 Aug 17.
5
Modelling Myc inhibition as a cancer therapy.将Myc抑制作为一种癌症治疗方法进行建模。
Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.
6
C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine.C-Myc是肠道中Apc缺失表型的关键介导因子。
Cancer Res. 2008 Jul 1;68(13):4963-6. doi: 10.1158/0008-5472.CAN-07-5558.
7
Module map of stem cell genes guides creation of epithelial cancer stem cells.干细胞基因模块图谱指导上皮癌干细胞的生成。
Cell Stem Cell. 2008 Apr 10;2(4):333-44. doi: 10.1016/j.stem.2008.02.009.
8
Integration of genome and chromatin structure with gene expression profiles to predict c-MYC recognition site binding and function.整合基因组和染色质结构与基因表达谱以预测c-MYC识别位点的结合及功能。
PLoS Comput Biol. 2007 Apr 6;3(4):e63. doi: 10.1371/journal.pcbi.0030063.
9
Myc deletion rescues Apc deficiency in the small intestine.Myc基因缺失可挽救小肠中的Apc基因缺陷。
Nature. 2007 Apr 5;446(7136):676-9. doi: 10.1038/nature05674. Epub 2007 Mar 21.
10
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.肿瘤中Myc依赖的血管生成开关由白细胞介素1β介导。
Genes Dev. 2006 Sep 15;20(18):2527-38. doi: 10.1101/gad.1455706.
Zotero 插件